Researchers at Adaptimmune, RPCI and City of Hope announced the opening of a Phase I/IIa clinical trial in ovarian cancer at RPCI and City of Hope. The team will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties.

Longtime Orchard Park resident Elyse NeMoyer has joined the Roswell Park Cancer Institute (RPCI) Board of Directors. An occupational therapist, she was appointed to a three-year term on the board by state Sen. Andrea Stewart-Cousins, Democratic Conference Leader for the New York State Senate, based on the recommendation of state Sen. Timothy Kennedy.

Cleveland BioLabs, Inc. (NASDAQ:CBLI), Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures, and Roswell Park Cancer Institute (RPCI) today announced the publication of studies describing the Facilitates Chromatin Transcription (FACT) complex as an accelerator of tumor transformation and a potential marker and target for aggressive cancers in Cell Reports, a peer-reviewed journal.

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma.

The University of Rochester Medical Center and Roswell Park Cancer Institute (RPCI) have received accreditation from the Accreditation Council for Graduate Medical Education (ACGME) for a joint two-year fellowship program in complex general surgical oncology.

America’s biopharmaceutical research companies have conducted more than 7,000 clinical trials of new medicines in New York over the last 13 years, working in collaboration with academic institutions, patient advocates, hospitals and clinical research facilities.

The Ride For Roswell, Roswell Park Cancer Institute’s largest fundraiser, welcomed more than 8,000 riders, who traveled on routes ranging from 3 to 100 miles today, each starting and ending at the University at Buffalo (UB), Amherst Campus.

Researchers at Roswell Park Cancer Institute (RPCI) have determined that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC), a complex procedure to treat advanced abdominal cancers, can be done safely, and may be an effective therapy for select patients. Study results are published in the June issue of Cancer Medicine.